The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.
S, A., M, E., A, H., S, A., B, R., W, A., T, J., & A, S. (2026). The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.. Journal of clinical apheresis. https://doi.org/10.1002/jca.70160
S A, M E, A H, S A, B R, W A, et al. The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.. Journal of clinical apheresis. 2026; doi: 10.1002/jca.70160
S A, M E, A H, et al. The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.[J]. Journal of clinical apheresis. 2026. DOI: 10.1002/jca.70160.
@article{s2026,
author = {Aslani S and Eslami M and Hatami A and Alizadeh S and Razi B and Almahmeed W and Jamialahmadi T and Sahebkar A},
title = {The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.},
journal = {Journal of clinical apheresis},
year = {2026},
doi = {10.1002/jca.70160},
note = {PMID: 42521472},
}
TY - JOUR AU - Aslani S AU - Eslami M AU - Hatami A AU - Alizadeh S AU - Razi B AU - Almahmeed W AU - Jamialahmadi T AU - Sahebkar A TI - The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis. T2 - Journal of clinical apheresis PY - 2026 DO - 10.1002/jca.70160 AN - PMID:42521472 ER -
Lipoprotein apheresis (LA) is used for severe dyslipidemia but can remove non-lipid plasma constituents. In this systematic review and meta-analysis, we synthesized evidence on LA-associated changes in albumin, total protein (TP), and α2-macroglobulin (α2M). PubMed, Scopus, and Web of Science were searched from inception to August 2025 for human observational studies reporting pre-/post-apheresis values for albumin, TP, or α2M. Pooled effects were summarized as weighted mean differences (WMD) with 95% CIs. Prespecified subgroup analyses included apheresis duration (≥ 1 year vs. < 1 year), disease background, and apheresis method. Twenty-eight publications met eligibility (albumin: 22 publications/39 studies; TP: 21 publications/34 studies; α2M: 6 publications/7 studies). LA was associated with lower post-procedure levels of albumin (WMD = -3.80 g/L; 95% CI: -4.61 to -2.99; p < 0.001), TP (WMD = -8.73 g/L; 95% CI: -11.06 to -6.41; p < 0.001), and α2M (WMD = -65.79 mg/dL; 95% CI: -88.98 to -42.60; p < 0.001). Reductions were observed across durations (< 1 year and ≥ 1 year), disease groups, and apheresis methods, with larger albumin decreases in DALI-based protocols and smaller in other methods. Between-study heterogeneity was high but diminished in several subgroups; meta-regression suggested background disease as a potential contributor. Across observational studies, LA reduced albumin, TP, and α2M immediately post-procedure. Magnitudes vary by method, clinical context, and treatment duration. These findings support routine monitoring of protein profiles during maintenance LA.